tradingkey.logo

Anbio Biotechnology

NNNN
25.650USD
+1.590+6.61%
Close 02/06, 16:00ETQuotes delayed by 15 min
1.13BMarket Cap
416.53P/E TTM

Anbio Biotechnology

25.650
+1.590+6.61%

More Details of Anbio Biotechnology Company

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Anbio Biotechnology Info

Ticker SymbolNNNN
Company nameAnbio Biotechnology
IPO dateFeb 19, 2025
CEOLau (Michael)
Number of employees27
Security typeOrdinary Share
Fiscal year-endFeb 19
AddressFriedrich-Ebert-Anlage 49
CityFRANKFURT AM MAIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code60308
Phone4916096247281
Websitehttps://anbiobiotechnology.com/
Ticker SymbolNNNN
IPO dateFeb 19, 2025
CEOLau (Michael)

Company Executives of Anbio Biotechnology

Name
Name/Position
Position
Shareholding
Change
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
European Union
5.62M
68.64%
South America
1.48M
18.02%
Asia Pacific
509.17K
6.22%
Other Regions
472.38K
5.77%
North America
110.51K
1.35%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
Other
90.33%
Shareholders
Shareholders
Proportion
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
Other
90.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.80%
Corporation
4.78%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.03%
Hedge Fund
0.02%
Venture Capital
0.02%
Other
90.27%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
12
2.17M
4.94%
+2.15M
2025Q3
8
2.13M
4.85%
+2.06M
2025Q2
5
4.27M
9.72%
+4.25M
2025Q1
5
4.27M
9.72%
+4.27M

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Northwestern Mutual Capital, LLC
2.10M
4.78%
+2.10M
--
Feb 19, 2025
CVC Investment
2.10M
4.78%
+2.10M
--
Feb 19, 2025
Geode Capital Management, L.L.C.
25.76K
0.06%
+8.63K
+50.40%
Sep 30, 2025
Marshall Wace LLP
10.44K
0.02%
+10.44K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
8.61K
0.02%
+8.21K
+2052.50%
Sep 30, 2025
Millennium Management LLC
7.08K
0.02%
+7.08K
--
Sep 30, 2025
XTX Markets LLC
6.90K
0.02%
+6.90K
--
Sep 30, 2025
HRT Financial LP
6.01K
0.01%
+6.01K
--
Sep 30, 2025
UBS Financial Services, Inc.
960.00
0%
-9.73K
-91.02%
Sep 30, 2025
BNP Paribas Securities Corp. North America
2.42K
0.01%
+1.16K
+91.83%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI